Teva Pharmaceutical Industries Limited (NYSE:TEVA) Expected to Post Q3 2025 Earnings of $0.61 Per Share

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Analysts at Zacks Research boosted their Q3 2025 earnings estimates for Teva Pharmaceutical Industries in a research note issued on Thursday, March 28th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.61 per share for the quarter, up from their previous forecast of $0.60. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2025 earnings at $0.77 EPS, FY2025 earnings at $2.39 EPS and FY2026 earnings at $2.71 EPS.

A number of other brokerages have also weighed in on TEVA. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price target for the company from $12.00 to $19.00 in a report on Monday, February 12th. HSBC started coverage on shares of Teva Pharmaceutical Industries in a report on Monday, December 18th. They set a “buy” rating and a $13.00 price target for the company. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price target for the company in a report on Friday, March 8th. Finally, Barclays upped their price target on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Monday, February 5th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $13.78.

Teva Pharmaceutical Industries Trading Down 2.2 %

Shares of TEVA opened at $14.11 on Friday. The firm has a market cap of $15.82 billion, a price-to-earnings ratio of -30.02, a PEG ratio of 1.63 and a beta of 1.04. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. Teva Pharmaceutical Industries has a fifty-two week low of $7.09 and a fifty-two week high of $14.45. The firm has a 50 day moving average price of $13.02 and a 200-day moving average price of $10.91.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.25. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. The business had revenue of $4.46 billion during the quarter, compared to analyst estimates of $3.97 billion.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the completion of the sale, the vice president now directly owns 1 shares in the company, valued at approximately $13.05. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, VP Eric Drape sold 173,261 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the sale, the vice president now owns 1 shares of the company’s stock, valued at approximately $13.05. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Mark Sabag sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the sale, the executive vice president now directly owns 382,590 shares in the company, valued at approximately $5,172,616.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 390,738 shares of company stock worth $5,132,766. 0.62% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently made changes to their positions in TEVA. BlackRock Inc. raised its position in shares of Teva Pharmaceutical Industries by 3.7% during the first quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock valued at $391,081,000 after buying an additional 1,494,814 shares during the last quarter. Phoenix Holdings Ltd. raised its position in shares of Teva Pharmaceutical Industries by 2.3% during the third quarter. Phoenix Holdings Ltd. now owns 34,481,692 shares of the company’s stock valued at $351,713,000 after buying an additional 778,282 shares during the last quarter. Lingotto Investment Management LLP raised its position in shares of Teva Pharmaceutical Industries by 1.8% during the fourth quarter. Lingotto Investment Management LLP now owns 34,457,656 shares of the company’s stock valued at $359,738,000 after buying an additional 607,800 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its position in shares of Teva Pharmaceutical Industries by 7.1% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock valued at $342,788,000 after buying an additional 2,188,212 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Teva Pharmaceutical Industries by 6.9% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock valued at $301,920,000 after buying an additional 1,860,000 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.